Revenue for Arexvy and Abrysvo fell sharply year over year in the fourth quarter due to narrower U.S. guidelines for their ...

One Zelienople child survived a serious health scare after coming down with respiratory syncytial virus in late January. The ...

Pfizer has bolstered the evidence behind its respiratory syncytial virus (RSV) vaccine with a positive trial of the shot used to protect newborns, adding to earlier results in older adults. The ...

Both vaccines made the bulk of their ... its first approval for the jab in adults aged 60 and over in the US on 3rd May, although, Abrysvo was only a few weeks behind with an FDA approval for ...

Welcome to the Merck & Company Q4 sales and earnings conference call. [Operator instructions] This call is being recorded.

Q4 2024 Earnings Call Transcript February 4, 2025 Merck & Co., Inc. misses on earnings expectations. Reported EPS is $1.72 ...

Inhalon Biopharma, Inc. (Inhalon), a clinical-stage company advancing a first ... in RSV, where vaccine usage is now expected to be one-third of original estimates. As many as 30-50% of immunized ...

FDA 2025 pulmonology drug alerts, including drug approvals/warnings, vaccine approvals, and medical device recalls/updates.

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has ...

Sanofi’s jump in earnings comes with an increased emphasis on R&D and vaccines, plus an eye cast toward M&A to shore up its pipeline.